SETMAR and metastatic malignant neoplasm in the lymph nodes: Correspondingly, the expression level of SETMAR was significantly associated with various clinical characteristics of thyroid cancer, including clinical stage (Figure S1C, Supporting Information), T stage (Figure S1D, Supporting Information), lymph node metastasis (Figure S1E, Supporting Information), BRAFV600E mutation (Figure S1F, Supporting Information), disease‐free survival (Figure 1D), and progression‐free survival (Figure 1E).